• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparison of patients with myeloma receiving zoledronic acid vs denosumab: a nationwide retrospective cohort study.

作者信息

Mohyuddin Ghulam Rehman, Guadamuz Jenny S, Ascha Mustafa S, Chiu Brian C-H, Patel Pritesh R, Sweiss Karen, Rohrer Rebecca, Sborov Douglas, Calip Gregory S

机构信息

Division of Hematology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.

Flatiron Health, New York, NY.

出版信息

Blood Adv. 2024 Nov 12;8(21):5539-5541. doi: 10.1182/bloodadvances.2024013600.

DOI:10.1182/bloodadvances.2024013600
PMID:39207867
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11539361/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7298/11539361/ea538fd0cc32/BLOODA_ADV-2024-013600-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7298/11539361/ea538fd0cc32/BLOODA_ADV-2024-013600-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7298/11539361/ea538fd0cc32/BLOODA_ADV-2024-013600-gr1.jpg

相似文献

1
Comparison of patients with myeloma receiving zoledronic acid vs denosumab: a nationwide retrospective cohort study.接受唑来膦酸与地诺单抗治疗的骨髓瘤患者比较：一项全国性回顾性队列研究。
Blood Adv. 2024 Nov 12;8(21):5539-5541. doi: 10.1182/bloodadvances.2024013600.
2
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.地舒单抗对比唑来膦酸在初诊多发性骨髓瘤骨病治疗中的应用：一项国际性、双盲、双模拟、随机、对照、3 期研究。
Lancet Oncol. 2018 Mar;19(3):370-381. doi: 10.1016/S1470-2045(18)30072-X. Epub 2018 Feb 9.
3
Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis.地舒单抗对比唑来膦酸在初诊多发性骨髓瘤骨病治疗中的应用：一项国际性、双盲、随机对照 3 期研究-亚洲亚组分析。
Adv Ther. 2020 Jul;37(7):3404-3416. doi: 10.1007/s12325-020-01395-x. Epub 2020 Jun 10.
4
Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study.地诺单抗与唑来膦酸对骨转移癌患者钙水平的影响：一项回顾性队列研究。
J Oncol Pharm Pract. 2019 Dec;25(8):1846-1852. doi: 10.1177/1078155218820927. Epub 2019 Jan 7.
5
Safety and efficacy of bone-modifying agents among multiple myeloma patients: A retrospective cohort study.骨修饰剂在多发性骨髓瘤患者中的安全性和有效性：一项回顾性队列研究。
J Oncol Pharm Pract. 2022 Apr;28(3):523-529. doi: 10.1177/1078155221996039. Epub 2021 Feb 16.
6
Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study.地舒单抗对比唑来膦酸在多发性骨髓瘤患者中的 PFS：一项国际 3 期研究的探索性结果。
Blood Adv. 2021 Feb 9;5(3):725-736. doi: 10.1182/bloodadvances.2020002378.
7
Efficacy and risk of osteonecrosis of the jaw for pamidronate, zoledronic acid, and denosumab in comparison to alendronate in multiple myeloma patients.与阿仑膦酸钠相比，帕米膦酸、唑来膦酸和地诺单抗在多发性骨髓瘤患者中导致颌骨坏死的疗效和风险。
Proc (Bayl Univ Med Cent). 2024 Feb 8;37(2):227-229. doi: 10.1080/08998280.2023.2298667. eCollection 2024.
8
The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.地舒单抗在预防转移性骨病癌症患者恶性高钙血症中的作用。
Eur J Cancer. 2015 Jul;51(11):1467-75. doi: 10.1016/j.ejca.2015.04.017. Epub 2015 May 11.
9
Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. A Commentary of the Pivotal Trial by Raje et al. Published on Lancet Oncology.接受地诺单抗或唑来膦酸治疗的骨髓瘤患者颌骨坏死。拉杰等人对关键试验的评论。发表于《柳叶刀·肿瘤学》。
Dent J (Basel). 2018 Sep 1;6(3):42. doi: 10.3390/dj6030042.
10
Risk of Cataract Surgery and Age-Related Macular Degeneration After Initiation of Denosumab vs Zoledronic Acid for Osteoporosis: A Multi-Database Cohort Study.地舒单抗与唑来膦酸治疗骨质疏松症起始后白内障手术和年龄相关性黄斑变性的风险：一项多数据库队列研究。
Drugs Aging. 2020 Apr;37(4):311-320. doi: 10.1007/s40266-020-00745-2.

引用本文的文献

1
Preventing Skeletal-Related Events in Newly Diagnosed Multiple Myeloma.预防新诊断多发性骨髓瘤的骨相关事件
Cells. 2025 Aug 15;14(16):1263. doi: 10.3390/cells14161263.

本文引用的文献

1
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.达雷妥尤单抗、硼替佐米、来那度胺和地塞米松治疗多发性骨髓瘤。
N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12.
2
Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead.癌症药物试验中的偏倚评估——将无进展生存期用作主要终点如何会产生误导。
JAMA Oncol. 2022 May 1;8(5):679-680. doi: 10.1001/jamaoncol.2021.8206.
3
Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study.
地舒单抗对比唑来膦酸在多发性骨髓瘤患者中的 PFS：一项国际 3 期研究的探索性结果。
Blood Adv. 2021 Feb 9;5(3):725-736. doi: 10.1182/bloodadvances.2020002378.
4
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group.多发性骨髓瘤相关骨病的治疗：国际骨髓瘤工作组骨工作组的建议。
Lancet Oncol. 2021 Mar;22(3):e119-e130. doi: 10.1016/S1470-2045(20)30559-3. Epub 2021 Feb 2.
5
Bones in Multiple Myeloma: Imaging and Therapy.多发性骨髓瘤中的骨骼：影像学与治疗
Am Soc Clin Oncol Educ Book. 2018 May 23;38:638-646. doi: 10.1200/EDBK_205583.
6
Denosumab for bone lesions in multiple myeloma - what is its value?地诺单抗用于多发性骨髓瘤骨病变——其价值何在？
Haematologica. 2018 May;103(5):753-754. doi: 10.3324/haematol.2017.185264.
7
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.地舒单抗对比唑来膦酸在初诊多发性骨髓瘤骨病治疗中的应用：一项国际性、双盲、双模拟、随机、对照、3 期研究。
Lancet Oncol. 2018 Mar;19(3):370-381. doi: 10.1016/S1470-2045(18)30072-X. Epub 2018 Feb 9.
8
Confounding in observational studies based on large health care databases: problems and potential solutions - a primer for the clinician.基于大型医疗保健数据库的观察性研究中的混杂因素：问题与潜在解决方案——临床医生入门指南
Clin Epidemiol. 2017 Mar 28;9:185-193. doi: 10.2147/CLEP.S129879. eCollection 2017.
9
The role of censoring on progression free survival: oncologist discretion advised.删失对无进展生存期的作用：建议肿瘤学家酌情处理。
Eur J Cancer. 2015 Nov;51(16):2269-71. doi: 10.1016/j.ejca.2015.07.005. Epub 2015 Aug 7.
10
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.唑来膦酸对比氯膦酸在多发性骨髓瘤（MRC Myeloma IX）一线治疗中的应用：一项随机对照试验。
Lancet. 2010 Dec 11;376(9757):1989-99. doi: 10.1016/S0140-6736(10)62051-X. Epub 2010 Dec 3.